Loading
A phase 2 trial of sintilimab, nab-paclitaxel and gemcitabine in pancreatic cancer, run by Shanghai Zhongshan Hospital, not yet recruiting.
Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic Cancer is a phase 2, interventional study registered as NCT05562297 by Shanghai Zhongshan Hospital, with a registry enrolment figure of 50 participants, started 2025-03-20 and due to reach its primary completion in 2027-10-01. Interventions recorded: sintilimab; nab-paclitaxel; gemcitabine. Conditions listed: Pancreatic Cancer, Stage IB; Pancreatic Cancer, Stage IIA; Pancreatic Cancer, Stage IIB; Pancreatic Cancer Stage III. Primary outcome: 2-year overall survival after the application of sintilimab and gemcitabine plus nab-paclitaxel. Pancreatic eligibility wording from the registry: "* Patients must have imaging evaluations to confirm that their pancreatic adenocarcinoma is resectable and borderline resectable". Sites: China. No results are recorded here; the registry entry is the source.
Shares Borderline resectable pancreatic ductal adenocarcinoma, Nab-paclitaxel, Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Sintilimab, Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Gemcitabine and the tag pancreatic-deep-dive.
Shares Borderline resectable pancreatic ductal adenocarcinoma, Nab-paclitaxel, Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Nab-paclitaxel, Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Gemcitabine and the tag pancreatic-deep-dive.
Shares Nab-paclitaxel, Pancreatic cancer trials open today (registry snapshot and UK sites), Gemcitabine, Cytotoxic chemotherapy and the tag pancreatic-deep-dive.
Shares Borderline resectable pancreatic ductal adenocarcinoma, Nab-paclitaxel, Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Gemcitabine, Cytotoxic chemotherapy and the tag pancreatic-deep-dive.
Shares Nab-paclitaxel, Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag pancreatic-deep-dive.